Thus, therapeutic targeting of LAMP3+ DCs might be only feasible in the early stage of NPC development so that effector lymphocytes can more effectively recognize the tumor antigens subsequently induce tumor depletion. This evidence concerns the gene LAMP3 and neoplasm.